Esbriet (pirfenidone) can improve survival rates of idiopathic pulmonary fibrosis (IPF) patients by 30 percent, a real-world retrospective analysis shows. The study, “Pirfenidone improves survival in IPF: results from a real-life study,” was published in the journal BMC Pulmonary Medicine. Genentech’s Esbriet is an approved…
Esbriet Extends IPF Patient Survival, Real-world Study Reports
With the holiday season upon us, the social gatherings have begun. An unofficial start to the holidays for me is attending my family Christmas dinner, which occurs on the last Saturday of November. Our extended family is too large to bring everyone together in December, so we…
Preclinical data show that treatment with Nuformix’s investigational candidates within the NXP002 program can prevent fibrosis progression with enhanced efficiency compared to the current standard of care, the company announced. The study, conducted in collaboration with researchers at Newcastle University, U.K., revealed that the new therapeutic agents…
Over a month ago, one of our readers, Mardy Sitzer, shared a wonderful idea with me. She graciously permitted me to share it with you. Like many of us, Mardy has had IPF for quite a while and is on oxygen 24/7. Her IPF is advanced enough…
Idiopathic pulmonary fibrosis (IPF) patients experience a significant decline in quality of life and worse symptom burden during the last months of life, a real-world study shows. The Finland-based study, “Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last…
With November coming to a close, I look forward to sharing with you the things I am grateful for as part of my continuing miniseries on gratitude. As I turn over my calendar to December, I can’t help but smile as I reflect on all the great things…
RXC006, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF) and other types of fibrosis, was seen to ease lung scarring in a mouse model of IPF, its developer, Redx Pharma, has announced. The investigative inhibitor is also reported to work favorably in human lung fibroblasts grown in the laboratory.
Middle-age adults with reduced respiratory function have up to a 27% higher risk of developing dementia or cognitive impairment later in life, a study suggests. This risk pattern is even more pronounced in patients with restrictive lung diseases such as idiopathic pulmonary fibrosis (IPF), according to the study, titled “…
When I was growing up, friends, family members, and teachers would tease me about my “fear of missing out” on opportunities. This was because I rarely turned down the chance to try something new. As I got a little older, I often committed to more than I could…
A herbal extract derived from a product used in Korean traditional medicine may be a potential alternative treatment for idiopathic pulmonary fibrosis (IPF), a mouse study suggests. The herbal extract was found to reduce inflammation and markers of lung fibrosis in a mouse model of PF…
